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4-O-methylhonokiol prevent cardiac hypertrophy via suppression of lipid
accumulation, oxidative stress and inﬂammation in obesity mice induced by
high fat diet
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Objectives: Obesity is associated with cardiac inﬂammation, oxidative stress,
apoptotic cell death, resulting in cardiac hypertrophy cardiac dysfunction. Magnolia
as a herbal material obtained from Magnolia ofﬁcinalis has been found to play an
important role in anti-inﬂammation, anti-oxidative stress, and anti-apoptosis. In our
previous study, we found that the extract of Magnolia (BL153) attenuated cardiac
lipid accumulation, inﬂammation, oxidative stress, apoptotic cell death and cardiac
hypertrophy in high-fat-diet (HFD) -induced obese mice. However, the extract
contains some toxic ingredients that may limit the use of the Magnolia extract. In the
present study, we investigated the preventive effect on of HFD-induced obesity-
associated insulin resistance, lipid accumulation and inﬂammation in the heart by
BL153 bioactive constituent, 4-O-methylhonokiol (MH), using BL153 as a
reference.
Methods: C57BL/6J mice, 8 weeks of age, were treated with vehicle, BL153
(5mg/kg), MH (0.5mg/kg) or MH (1.0mg/kg) by gavage daily, during 24weeks of
normal (10 kcal% fat) fat diet or HFD (60 kcal% fat) feeding. At the endpoint
blood glucose, glucose tolerance, plasma triglyceride and cardiac function were
assessed. Cardiac lipid accumulation was measured by Oil Red O staining.
Cardiac ﬁbrosis, inﬂammation, and oxidative damage were assessed by Western
blot.
Results: 0.5mg/kg MH treatment signiﬁcantly ameliorated insulin resistance with
slightly decreased of body weight gain induced by HFD feeding. MH signiﬁcantly
attenuated HFD-induced hypertriglyceridemia and hypercholesteremia. MH treat-
ments ameliorated cardiac hypertrophy. MH treatments also attenuated cardiac lipid
accumulation through inhibiting the expression of fatty acid translocase / D36 and
evaluating the expression of peroxisome proliferator-activated receptor g coactivator 1
a (PGC1a) and suppressed oxidative stress markers (malondialdehyde) by increasing
nuclear-factor-E2-related-factor-2 (Nrf2) and inﬂammation markers (tumor necrosis
factor-a and plasminogen activator inhibitor-1).
Conclusions: Our study indicated that MH ameliorated HFD associated cardiac hy-
pertrophy cardiac lipid accumulation, inﬂammation, oxidative stress via down-
regulation of CD36 and upregulation of PGC1a and Nrf2.
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Objectives: The aim of this study was to determine the effect of berberine on
Ab1-40 and Ab1-42 in the extractcellular ﬂuid of mouse neuroblastoma N2A
Swedish mutant (APPsw) cells (N2a-APP695), a widely used AD model in
vitro. We also detected the transcriptional and translational regulation of IDE
and PPAR-gamma expression after the treatment of N2a-APP695 cells with
berberine.
Methods: We used different concentrations of berberine treated with N2a-APP695
cells, and then used the Ab ELISA KIT detected the concentrations of Ab1-40 and
Ab1-42, subsequently used Western Blotting and RT-PCR tested the amount of IDE
and PPAR-gamma in different groups.
Results: The result showed that berberine decreased the levels of Ab1-40 and Ab1-42
in a dose-dependent manner. Compared with the 0mM berberine group, 10mM
berberine groups Ab40 decreased 33.61  7.68% and Ab42 decreased 39.40 
1.32%. To illuminate the reasons of berberine decreasing the levels of Ab1-40 and
Ab1-42 in the extracellular ﬂuid of N2a-APP695, the regulation of berberine on
IDE was studied in vitro in N2a-APP695 cells. Results indicated that berberine can
up-regulate IDE protein in both dose-dependent and time-dependent in N2a-APP695
cells, and also up-regulated the IDE-mRNA. Subsequently the experimental result
showed that berberine can up-regulate the expression of PPAR-gamma in N2a-
APP695 cells. 10mM berberine increased the expression of PPAR-gamma by
46.380.39% as controlled with 0mM berberine.
Conclusions: These experiments describe that berberine through activating PPAR-
gamma pathway can up-regulate the protein expression of IDE and then promote the
degradation of Ab, thereby reducing the level of Ab in the extracellular medium of
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S-Propargyl-cysteine (SPRC) diminishes mitochondrial dysfunctions in
heart failure
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Objectives: One of the important factors of heart failure (HF) is mitochondrial
dysfunction. Growing evidences indicate that damage of mitochondria causes mito-
chondrial pathway apoptosis and the loss of cardiomyocytes, which are signiﬁcant in
the process of HF. At the meantime, the injury of mitochondrial respiratory chain
results in a decrease of cellular ATP level in HF. Hydrogen sulﬁde (H2S) is the
third gasotransmitter, which presents a wide range of cell function in the body.
S-Propargyl-cysteine (SPRC) is water-soluble H2S endogenous donor which has
protective effect on acute myocardial infarction in rats. The aim of this study was to
investigate how SPRC diminishes mitochondrial dysfunctions in HF.
Methods: HF in C57BL/6 mice (male, 6-8 weeks old) was induced by Isoprenaline
(7.5 mg/kg), which was administered for 3 weeks, once a day by subcutaneous in-
jection. Hydrogen peroxide (H2O2) 200mM was used to induce Myocardial oxidative
damage in H9c2 cells. H&E stain and masson trichrome stain were used to determine
the histopathological change. Cell viability assay was used to determine the protective
effect of SPRC in vitro. Caspase activity assay was used to determine the apoptosis
level. Lipid peroxidation, antioxidant enzymes, ATP level, mitochondrial DJm
measurement and mitochondrial respiratory chain complexes (I-IV) measurement
were used to determine the mitochondrial function. Western blot was used to deter-
mine the expression levels of Bcl-2, Bax, pro-Caspase 3/9 and PKCε.
Results: H&E stain and masson trichrome stain showed a signiﬁcant loss of
myocardium and increased ﬁbrosis in isoproterenol group compared with the vehicle
group. After SPRC (10, 25 mg/kg) treatment, the level of myocardial ﬁbrosis was
signiﬁcantly reduced. SPRC (10 - 50 mM) were found to increase cell viability
signiﬁcantly, which reduced by H2O2 in H9c2 cells. SPRC (10, 25 mg/kg) signiﬁ-
cantly decreased the level of apoptosis in mice compared to the model group. The
same result was observed in SPRC (10 - 50 mM) treated H9c2 cells. The level of
mitochondrial glutathione (GSH) and superoxide dismutase (SOD) was recovered by
SPRC treatment and the content of mitochondrial lipid peroxidation (LPO) was
decreased compared with H2O2 group. The content of ATP and the activity of
mitochondrial respiratory chain complexes were signiﬁcantly increased in SPRC
treated grouped which were severely reduced in H2O2 group. The mitochondrial
membrane potential was signiﬁcantly reduced and the calcium swelling was markedly
decreased in the SPRC groups. SPRC induced translocation of PKCε to mitochondria,
which reduced by H2O2.
Conclusions: This study suggests the therapeutic ability of SPRC in HF through the
protective effect of mitochondrial dysfunction.
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Growth hormone releasing hormone agonist enhances cell survival and
anti-apoptosis of bone marrow derived mesenchymal stem cells via activating
STAT3 signaling pathway to promote angiogenesis of hindlimb ischemia
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Objectives: growth hormone releasing hormone (GHRH) is an endocrine hormone
produced by pituitary gland and stored and released to the circulatory system by
hypothalamus and GHRH receptor has been conﬁrmed to exist on cardiomyocytes and
mesenchymal stem cells to adjust the functions of these cells. The effectiveness of
MSC transplantation has been limited to a relative low level main by the restricted
survival rate after injection. As to an artiﬁcially synthesized polypeptide compound,
the GHRH analogue JI-34 is better at the stability and stimulating efﬁciency through by
less degradation compared with physiological GHRH. Therefore, to testify a newly use
of GHRH agonist JI-34 whether it can enhance the survival of MSC will be attractive.
Methods: the survival, viability, migration angiogenesis ability and anti-apoptosis rate
of MSC is compared between two groups of mice MSC pretreated with JI-34 or not.
CCK-8, transwell assay, Western blot, quantitive RT-PCR, tube formation assay and
TUNEL staining kit were used in this paper. In vivo study we revealed the angio-
genesis ability of pretreated MSC by cell injection into ischemic hindlimb of 6 weeks
old C57/BL6 mice.
Results: After JI-34 pretreatment for 24hours, MSC’s viability had increased by
23%0.5% compared with controls in normoxia condition and 26%1% in
hypoxia conditions (0.5% O2). Cell migration capacity can also be raised after
pretreatment of JI-34 in transwell chamber with a relatively increased 27%2%
migration rate in a 24hour’s assay with 10% gradient of Fetal Bovine Serum
(FBS). Similarly, the supernatants of MSC pretreated with JI-34 co-cultured
with Human Umbilical Vein Endothelial Cells (HUVEC) depicted a higher
possibility of tube formation with longer tube length (754mm37mm) than
control ones (580mm40mm) in each visual ﬁeld on the matrigel. RT-PCR and
Western Blot showed that a highly augment of pro-angiogenic factors of
VEGF-A and SDF-1 with 8 fold and 7.5 fold increase relating to control
respectively. All these effects can be blocked by adding the speciﬁc antagonist
of JI-34, MIA602 to shut down the beneﬁts of JI-349. western blot showed that
STAT3 and other signaling pathway molecules acted as the switch could be
activated in 10minutes and picked at 30minutes, stayed for about 2 hours then
gradually turned down to the normal level. By adding speciﬁc inhibitor ofer 16–19, 2014 j GW-ICC Abstracts/Basic and Translational Medicine
